Cingulate (CING) Non-Current Debt (2023 - 2025)
Cingulate's (CING) quarterly Non-Current Debt came in at $1.2 million in Q4 2025, down 52.75% YoY from $2.4 million in Q4 2024, and up 24.66% on a QoQ basis from $923698.0 in Q1 2025.
Cingulate (CING) Non-Current Debt (2023 - 2025) Analysis & Trends
Cingulate (CING) has 3 years of Non-Current Debt data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Non-Current Debt fell 52.75% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 52.75% YoY) and the FY2025 annual result came in at $1.2 million, down 52.75% from the prior year.
- Non-Current Debt improved to $1.2 million in Q4 2025, from $923698.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $2.4 million in Q4 2024 to a low of $923698.0 in Q1 2025.
- A 3-year average of $1.7 million and a median of $2.1 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt advanced 16.04% — and 2025, when it slumped 52.75%.
- Tracing CING's Non-Current Debt over 3 years: stood at $2.1 million in 2023, then rose by 16.04% to $2.4 million in 2024, then tumbled by 52.75% to $1.2 million in 2025.
- The last three Non-Current Debt figures came in at $1.2 million (Q4 2025), $923698.0 (Q1 2025), and $2.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 923,698.00 |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Sep 30, 2023 | 2.10 Mn |